GRIFOLS S A/S (NASDAQ:GRFS) Downgraded by ValuEngine to “Sell”

ValuEngine cut shares of GRIFOLS S A/S (NASDAQ:GRFS) from a hold rating to a sell rating in a research report released on Thursday, ValuEngine reports.

GRFS has been the subject of a number of other research reports. BidaskClub downgraded GRIFOLS S A/S from a strong-buy rating to a buy rating in a report on Monday, July 15th. JPMorgan Chase & Co. raised GRIFOLS S A/S from a neutral rating to an overweight rating and raised their target price for the company from $21.00 to $22.50 in a report on Thursday, June 27th. Finally, Zacks Investment Research raised GRIFOLS S A/S from a sell rating to a hold rating in a report on Wednesday, July 24th. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. GRIFOLS S A/S has an average rating of Hold and a consensus target price of $20.75.

NASDAQ:GRFS traded down $0.40 during midday trading on Thursday, reaching $22.28. The stock had a trading volume of 1,352,569 shares, compared to its average volume of 2,189,385. The business’s fifty day simple moving average is $21.28. GRIFOLS S A/S has a 12-month low of $17.42 and a 12-month high of $23.03. The company has a current ratio of 2.87, a quick ratio of 1.13 and a debt-to-equity ratio of 1.41. The stock has a market cap of $15.65 billion, a PE ratio of 19.04, a P/E/G ratio of 1.37 and a beta of 1.11.

GRIFOLS S A/S (NASDAQ:GRFS) last posted its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported $0.25 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.25. GRIFOLS S A/S had a net margin of 12.35% and a return on equity of 15.49%. The firm had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.29 billion. As a group, sell-side analysts expect that GRIFOLS S A/S will post 1.26 EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the business. Advisors Asset Management Inc. lifted its holdings in GRIFOLS S A/S by 40.8% in the first quarter. Advisors Asset Management Inc. now owns 5,108 shares of the biotechnology company’s stock valued at $103,000 after acquiring an additional 1,479 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in GRIFOLS S A/S by 9.1% in the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,296 shares of the biotechnology company’s stock valued at $127,000 after acquiring an additional 526 shares during the period. Mercer Global Advisors Inc. ADV acquired a new stake in GRIFOLS S A/S in the first quarter valued at $240,000. Amundi Pioneer Asset Management Inc. acquired a new stake in GRIFOLS S A/S in the fourth quarter valued at $242,000. Finally, Quadrant Capital Group LLC raised its stake in shares of GRIFOLS S A/S by 15.6% during the 1st quarter. Quadrant Capital Group LLC now owns 16,291 shares of the biotechnology company’s stock worth $318,000 after buying an additional 2,193 shares during the last quarter. 19.01% of the stock is owned by institutional investors.

About GRIFOLS S A/S

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.

Further Reading: What is Call Option Volume?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.